Similar articles

• The FDA Breakthrough-Drug Designation - Four Years of Experience.

  Darrow JJ, Avorn J, Kesselheim AS. Darrow JJ, et al. N Engl J Med. 2018 Apr 12;378(15):1444-1453. doi: 10.1056/NEJMhpr1713338. N Engl J Med. 2018. PMID: 29641970 No abstract available.
• New FDA breakthrough-drug category--implications for patients.

  Darrow JJ, Avorn J, Kesselheim AS. Darrow JJ, et al. N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493. N Engl J Med. 2014. PMID: 24670173 No abstract available.
• The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?

  Orlando VI. Orlando VI. Am J Law Med. 1999;25(4):543-68. Am J Law Med. 1999. PMID: 10629734 No abstract available.
• Eyes on New Product Development: Preclinical Research.

  Novack GD. Novack GD. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):4-6. doi: 10.1089/jop.2017.29039.gdn. Epub 2018 Jan 29. J Ocul Pharmacol Ther. 2018. PMID: 29377737 Review. No abstract available.
• The role of the pharmaceutical industry in drug development in dermatology.

  Cauwenbergh G. Cauwenbergh G. Clin Dermatol. 2002 Sep-Oct;20(5):467-73. doi: 10.1016/s0738-081x(02)00276-6. Clin Dermatol. 2002. PMID: 12435516 Review. No abstract available.